Skip to main content
Premium Trial:

Request an Annual Quote

NSF's New Acting Director

ScienceInsider reports that the US National Science Foundation has tapped Cora Marrett, a sociologist and academic administrator, to serve as its acting director after current head Subra Suresh steps down on March 22 until a permanent replacement is appointed and confirmed.

Suresh is vacating the role after holding it for two and half years to become the president of Carnegie Mellon University.

Marrett is the deputy director of the NSF, a post she's occupied since 2009. This isn't the first time that she has managed the institution while its leadership changed hands, according to the article. She was in charge in between the departure of former head Arden Bement in May 2010 and Suresh taking over in October of the same year. She's also run education programs and headed up the NSF's social and behavioral sciences directorate.

ScienceInsider adds that some former directors say Marrett should take over the role on a permanent basis, though it notes that only one deputy has become director throughout the agency's history.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.